APA

Bernhardt G., Gust R., Reile H., vom Orde H. D., Müller R., Keller C., Spruss T., Schönenberger H., Burgemeister T. & Mannschreck A. (19920417). [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line. : Journal of cancer research and clinical oncology.

Chicago

Bernhardt G, Gust R, Reile H, vom Orde H D, Müller R, Keller C, Spruss T, Schönenberger H, Burgemeister T and Mannschreck A. 19920417. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line. : Journal of cancer research and clinical oncology.

Harvard

Bernhardt G., Gust R., Reile H., vom Orde H. D., Müller R., Keller C., Spruss T., Schönenberger H., Burgemeister T. and Mannschreck A. (19920417). [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line. : Journal of cancer research and clinical oncology.

MLA

Bernhardt G, Gust R, Reile H, vom Orde H D, Müller R, Keller C, Spruss T, Schönenberger H, Burgemeister T and Mannschreck A. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line. : Journal of cancer research and clinical oncology. 19920417.